Literature DB >> 11954855

Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis.

Oscar Fernández1.   

Abstract

The majority of patients with multiple sclerosis (MS) suffer from lower urinary tract symptoms and sexual dysfunction at some stage of the disease. This has a negative impact on the quality of life of patients as well as causing concern to caregivers and family. Neurologists can now treat most of these symptoms by a number of pharmacological and nonpharmacological methods. This review presents the neuroanatomy, neurophysiology, neuropharmacology and pathophysiology of the urinary bladder and sexual organs, and the biological mechanisms underlying urogenital dysfunction in MS patients. Current treatment options for urinary and sexual dysfunction are reviewed. As most urogenital symptoms of MS can now be treated by conservative means, expert urological or gynaecological consultation should be requested only if more aggressive diagnostic or therapeutic measures are needed.

Entities:  

Mesh:

Year:  2002        PMID: 11954855     DOI: 10.1007/pl00007835

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

Review 1.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Pathophysiology of overactive bladder.

Authors:  Mai A Banakhar; Tariq F Al-Shaiji; Magdy M Hassouna
Journal:  Int Urogynecol J       Date:  2012-02-07       Impact factor: 2.894

Review 3.  Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines.

Authors:  Shachar Moshe Aharony; Ornella Lam; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 4.  A urological challenge: Voiding dysfunction in multiple sclerosis.

Authors:  Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2013-09       Impact factor: 1.862

5.  Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study.

Authors:  D Francomano; A Ilacqua; A Cortese; G Tartaglia; A Lenzi; M Inghilleri; A Aversa
Journal:  J Endocrinol Invest       Date:  2016-10-17       Impact factor: 4.256

6.  Bladder dysfunction in mice with experimental autoimmune encephalomyelitis.

Authors:  Cengiz Z Altuntas; Firouz Daneshgari; Guiming Liu; Adebola Fabiyi; Michael Kavran; Justin M Johnson; M Fatih Gulen; Ritika Jaini; Xiaoxia Li; Tara L Frenkl; Vincent K Tuohy
Journal:  J Neuroimmunol       Date:  2008-10-15       Impact factor: 3.478

Review 7.  Autonomic dysfunction in multiple sclerosis.

Authors:  Carl-Albrecht Haensch; Johannes Jörg
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

Review 8.  Improving MS patient care.

Authors:  Peter Rieckmann
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

9.  Grey and White Matter Magnetisation Transfer Ratio Measurements in the Lumbosacral Enlargement: A Pilot In Vivo Study at 3T.

Authors:  Chinyere O Ugorji; Rebecca S Samson; Martina D Liechti; Jalesh N Panicker; David H Miller; Claudia A M Wheeler-Kingshott; Marios C Yiannakas
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

10.  The use of the lumbosacral enlargement as an intrinsic imaging biomarker: feasibility of grey matter and white matter cross-sectional area measurements using MRI at 3T.

Authors:  Marios C Yiannakas; Puneet Kakar; Luke R Hoy; David H Miller; Claudia A M Wheeler-Kingshott
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.